Silencing TGF-β1 was reported to be not only a promising therapeutic approach to enhance efficacy of antitumor activity [23, 24], but also for renal fibrotic disease [25] and liver fibrosis [26]. Here, TGFB1 is linked to Hepatic fibrosis.